- Home
- MYNZ vs FLGC Comparison
MYNZ vs FLGC Comparison
Compare MYNZ & FLGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- FLGC
- Stock Information
- Founded
- MYNZ 2021
- FLGC 2019
- Country
- MYNZ Germany
- FLGC United States
- Employees
- MYNZ N/A
- FLGC N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- FLGC Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- FLGC Health Care
- Exchange
- MYNZ Nasdaq
- FLGC Nasdaq
- Market Cap
- MYNZ 16.0M
- FLGC 17.3M
- IPO Year
- MYNZ 2021
- FLGC 2021
- Fundamental
- Price
- MYNZ $5.74
- FLGC $0.87
- Analyst Decision
- MYNZ Buy
- FLGC Strong Buy
- Analyst Count
- MYNZ 3
- FLGC 4
- Target Price
- MYNZ $14.00
- FLGC $5.67
- AVG Volume (30 Days)
- MYNZ 361.6K
- FLGC 276.0K
- Earning Date
- MYNZ 04-15-2025
- FLGC 03-27-2025
- Dividend Yield
- MYNZ N/A
- FLGC N/A
- EPS Growth
- MYNZ N/A
- FLGC N/A
- EPS
- MYNZ N/A
- FLGC N/A
- Revenue
- MYNZ $917,203.00
- FLGC $64,154,000.00
- Revenue This Year
- MYNZ $21.95
- FLGC N/A
- Revenue Next Year
- MYNZ $30.77
- FLGC $8.94
- P/E Ratio
- MYNZ N/A
- FLGC N/A
- Revenue Growth
- MYNZ 16.23
- FLGC N/A
- 52 Week Low
- MYNZ $0.18
- FLGC $0.72
- 52 Week High
- MYNZ $8.20
- FLGC $2.93
- Technical
- Relative Strength Index (RSI)
- MYNZ 48.77
- FLGC 45.99
- Support Level
- MYNZ $5.08
- FLGC $0.80
- Resistance Level
- MYNZ $8.16
- FLGC $0.99
- Average True Range (ATR)
- MYNZ 1.10
- FLGC 0.09
- MACD
- MYNZ -0.23
- FLGC 0.02
- Stochastic Oscillator
- MYNZ 21.15
- FLGC 39.16
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are; the commercial and wholesale segment (FGH and Cosechemos subsidiaries), the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries), and the pharmaceuticals segment (Grupo Farmaceutico Cronomed and Breeze Laboratory subsidiaries). Geographically, the company generates revenue from United States, Germany, and the United Kingdom. It derives a majority of its revenue from the United States.